New drug combo aims to stall Hard-to-Treat prostate cancer

NCT ID NCT05502315

First seen Nov 05, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tests whether combining two drugs, cabozantinib and nivolumab, can slow the growth of advanced prostate cancer that has stopped responding to hormone therapy. About 47 men with metastatic castration-resistant prostate cancer will receive the combination. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California San Diego

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Email: •••••@•••••

    Contact

    Contact

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

    Contact Email: •••••@•••••

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact

    Contact Email: •••••@•••••

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53705, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.